| 摘要 |
The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitor, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor and further provides methods for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound.
|
